Neurocrine Biosciences, an American biopharmaceutical company, agreed to invest $175m in Voyager Therapeutics, a biotechnology company. “This new collaboration with Voyager encompassing GBA1-mediated diseases such as Parkinson’s disease and Gaucher’s disease complements our existing collaboration around Friedreich’s Ataxia and other CNS targets, establishing the foundation for a strong franchise of next-generation gene therapies utilizing Voyager’s TRACER capsids to treat serious neurological diseases. We believe GBA1 gene therapy has the potential to play a transformational role in the future treatment of Parkinson’s disease and other serious neurological diseases,” Jude Onyia, Neurocrine Biosciences Chief Scientific Officer.